Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Melanoma 1Bone Neoplasms 1

Interventions

pembrolizumab 3poly ICLC 2fludarabine 2belinostat 2aflibercept 2Radiosurgery 2Fluorodeoxyglucose F18 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2vocimagene amiretrorepvec 1tremelimumab 1trastuzumab deruxtecan 1seribantumab 1rucaparib 1romidepsin 1resiquimod 1palbociclib 1etoposide phosphate 1entinostat 1durvalumab 1ciforadenant 1cemiplimab 1cc-486 1avelumab 1amminedichloro(2-methylpyridine)platinum(II) 1Trastuzumab 1Thalidomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Histocompatibility Testing × Sarcoma × Clear all
NCT05819827 2025-04-27

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Mayo Clinic

Terminated
13 enrolled
DermatologicGenitourinarySarcoma

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡